Curcumin Added to Standard Endometriosis Drug Cuts Pain and Boosts Quality of Life
An 8-week RCT finds nanocurcumin plus dienogest significantly reduces dysmenorrhea, pelvic pain, and improves sexual function vs. drug alone.
Summary
A randomized, double-blind trial tested whether adding nanocurcumin (80 mg/day) to the standard endometriosis drug dienogest could improve outcomes beyond the drug alone. Eighty-six women with stage 2–3 endometriosis and moderate-to-severe pain were enrolled for 8 weeks. The curcumin combination group showed significantly greater reductions in dysmenorrhea, chronic pelvic pain, dyspareunia, and dyschezia compared to placebo plus dienogest. Quality of life and sexual function scores also improved meaningfully, though endometrioma size did not change significantly. The findings suggest curcumin may be a safe, accessible adjunct to hormonal therapy for endometriosis, offering clinicians and patients a potential tool to enhance pain control and wellbeing without adding pharmaceutical burden.
Detailed Summary
Endometriosis affects roughly 10% of reproductive-age women worldwide, causing chronic pelvic pain, painful intercourse, and diminished quality of life. Standard hormonal treatments like dienogest help but often fall short of full symptom relief, leaving many patients searching for complementary options. Curcumin, the active compound in turmeric, has shown anti-inflammatory and anti-estrogenic properties in preclinical models of endometriosis, but rigorous clinical evidence has been lacking — until now.
This randomized, double-blind, placebo-controlled trial enrolled 86 women aged 18–45 with stage 2–3 pelvic endometriosis and moderate-to-severe pain (VAS ≥ 4). Participants were assigned 1:1 to receive either nanocurcumin soft gel capsules (80 mg/day) or placebo, both alongside standard dienogest (2 mg/day), for 8 weeks. Nanocurcumin formulation was used to address curcumin's notoriously poor bioavailability.
Results were striking across multiple pain domains. The curcumin group showed significantly greater reductions in dysmenorrhea (aMD: −1.55), chronic pelvic pain (aMD: −1.55), dyspareunia (aMD: −0.93), and dyschezia (aMD: −0.30) compared to placebo. Quality of life scores and Female Sexual Function Index (FSFI) scores also improved significantly, with the exception of the orgasm domain. Notably, endometrioma size did not differ significantly between groups, suggesting the benefits are symptom-driven rather than structural.
For clinicians, these findings open a practical avenue: nanocurcumin at a modest dose may meaningfully amplify the therapeutic effect of first-line hormonal therapy without adding pharmaceutical complexity or known serious side effects. For patients, it represents a potentially accessible, low-risk adjunct.
Caveats include the short 8-week duration, which limits conclusions about long-term efficacy or safety. The study was conducted at a single center in Iran, which may affect generalizability. Additionally, this summary is based on the abstract only, so full methodological details, adverse event data, and dropout rates could not be assessed.
Key Findings
- Nanocurcumin added to dienogest reduced dysmenorrhea and chronic pelvic pain scores by ~1.55 points (VAS) vs. placebo.
- Dyspareunia improved significantly with curcumin add-on (aMD: −0.93), enhancing sexual comfort.
- Quality of life and overall Female Sexual Function Index scores improved significantly with combination therapy.
- Endometrioma lesion size did not change significantly, suggesting symptom relief without structural regression.
- An 80 mg/day nanocurcumin dose was sufficient to produce clinically meaningful benefits over 8 weeks.
Methodology
This was an 8-week randomized, double-blind, placebo-controlled trial with 86 women (1:1 allocation) comparing nanocurcumin 80 mg/day plus dienogest 2 mg/day versus placebo plus dienogest. Outcomes included VAS pain scores for multiple pain types, quality of life measures, and the Female Sexual Function Index (FSFI), analyzed using adjusted mean differences with 95% confidence intervals.
Study Limitations
The trial lasted only 8 weeks, making it impossible to assess long-term efficacy, safety, or durability of benefit. The single-center design in Iran may limit generalizability to other populations. This summary is based on the abstract only; full data on adverse events, dropout rates, and compliance could not be reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.